Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response
Year: 2018
Type: article
Source: Arthritis Care & Research
DOI: 10.1002/acr.23467
Authors: Melanie H. Smith, Anne R. Bass
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune-related adverse events, immune checkpoint inhibitors, cancer immunotherapy, musculoskeletal manifestations, arthritis, polyarthritis, oligoarthritis, tenosynovitis, polymyalgia rheumatica, corticosteroid therapy, steroid-sparing agents, nivolumab, pembrolizumab, durvalumab, ipilimumab, tremelimumab, antinuclear antibodies, anti-CCP antibodies, symptom duration
Open Access status: closed
OpenAlex ID: W2767736444
